Latest Period
Q1 2026
Security Snapshot
BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (BLTE) Institutional Ownership
CUSIP: 07782B104
13F Institutional Holders and Ownership History from Q2 2022 to Q1 2026
Institutions Reporting
75
Shares (Excl. Options)
9,116,527
Price
$159.44
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, par value US$0.0001 per share
- Symbol
- BLTE on Nasdaq
- Shares outstanding
- 40,449,516
- Reported price per share
- $168.76
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 9,116,527
- Total reported value
- $1,422,171,091
- Portfolio coverage rank
- 0%
- Share change
- +1,897,756
- Value change
- +$301,669,955
- Number of holders
- 75
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- BLTE - BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share is tracked under CUSIP 07782B104.
- 75 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 70 to 75 between Q4 2025 and Q1 2026.
- Reported value moved from $1,153,000,250 to $1,422,171,091.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 75 institutions filings for Q1 2026.
Security key
07782B104
Latest holder period
Q1 2026
13F holders
75
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
BLTE full holder history
BELITE BIO, INC SEC filings
BELITE BIO, INC company facts
BELITE BIO, INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 07782B104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
BLTE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $1,065,034,885 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 8.1% | +16% | $479,467,205 | +$65,024,200 | 3,027,704 | +16% | Darwin Global Management, Ltd. | 31 Dec 2025 |
| Lin Yu-Hsin | 3.1% | -57% | $212,905,624 | -$175,415,992 | 1,253,935 | -45% | Yu-Hsin Lin | 31 Mar 2026 |
As of 31 Mar 2026, 75 institutional investors reported holding 9,116,527 shares of BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (BLTE). This represents 23% of the company’s total 40,449,516 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
22%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 7.6% | 3,057,412 | +0.98% | 12% | $456,104,722 |
| Paradigm Biocapital Advisors LP | 2.8% | 1,114,784 | 3.6% | $177,741,161 | |
| UBS Group AG | 1.9% | 768,359 | +497% | 0.02% | $122,507,159 |
| RTW INVESTMENTS, LP | 1.8% | 715,332 | 0% | 1.1% | $114,052,534 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 570,088 | +2% | 0.07% | $90,894,831 |
| Holocene Advisors, LP | 1.2% | 494,495 | +488% | 0.19% | $78,842,283 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.88% | 357,650 | -6.6% | 0.94% | $57,023,716 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.75% | 304,013 | +30% | 0.57% | $48,471,833 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.7% | 281,805 | 0.01% | $44,931,000 | |
| MORGAN STANLEY | 0.5% | 201,409 | +619% | 0% | $32,112,649 |
| PERCEPTIVE ADVISORS LLC | 0.38% | 151,979 | -63% | 0.48% | $24,231,532 |
| Patient Square Capital LP | 0.29% | 116,684 | 3.3% | $18,604,097 | |
| Duquesne Family Office LLC | 0.26% | 106,100 | 0.58% | $16,917,000 | |
| GOLDMAN SACHS GROUP INC | 0.26% | 105,509 | +137% | 0% | $16,822,355 |
| MPM BIOIMPACT LLC | 0.22% | 88,045 | +0.32% | 1.1% | $14,037,895 |
| Affinity Asset Advisors, LLC | 0.16% | 65,000 | +225% | 0.61% | $10,363,600 |
| FRED ALGER MANAGEMENT, LLC | 0.15% | 62,574 | -21% | 0.04% | $9,976,799 |
| PFM Health Sciences, LP | 0.15% | 59,432 | +200% | 1% | $9,475,838 |
| RENAISSANCE TECHNOLOGIES LLC | 0.13% | 52,000 | 0.01% | $8,290,880 | |
| Longaeva Partners L.P. | 0.08% | 33,492 | 0.26% | $5,339,964 | |
| TD Asset Management Inc | 0.08% | 33,410 | 0% | $5,326,890 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.08% | 32,525 | 0% | 0% | $5,185,786 |
| ADAR1 Capital Management, LLC | 0.07% | 26,880 | -33% | 0.26% | $4,285,747 |
| Artia Global Partners LP | 0.06% | 24,989 | +39% | 0.9% | $3,984,246 |
| Quadrature Capital Ltd | 0.06% | 23,708 | -4.5% | 0.04% | $3,780,004 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Latest
Q1 2026
Rows shown
1-16 of 16
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 9,116,527 | $1,422,171,091 | +$301,669,955 | $159.44 | 75 |
| 2025 Q4 | 7,191,642 | $1,153,000,250 | +$810,023,763 | $159.96 | 70 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | $74.00 | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,966 | $57.70 | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | $66.22 | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | $63.10 | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | $46.88 | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,161 | $45.68 | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$4,083,463 | $38.37 | 11 |
| 2023 Q4 | 155,109 | $7,095,600 | +$3,531,143 | $45.75 | 17 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,075 | $31.85 | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,158 | $14.29 | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | $29.90 | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,675 | $30.15 | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,624 | $33.76 | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,000 | $31.13 | 6 |